CA2431113A1 - Method and immunoassay employing polystyrene nano-particles - Google Patents
Method and immunoassay employing polystyrene nano-particles Download PDFInfo
- Publication number
- CA2431113A1 CA2431113A1 CA002431113A CA2431113A CA2431113A1 CA 2431113 A1 CA2431113 A1 CA 2431113A1 CA 002431113 A CA002431113 A CA 002431113A CA 2431113 A CA2431113 A CA 2431113A CA 2431113 A1 CA2431113 A1 CA 2431113A1
- Authority
- CA
- Canada
- Prior art keywords
- particles
- polystyrene nano
- coated
- protein
- assay
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000004793 Polystyrene Substances 0.000 title claims description 76
- 229920002223 polystyrene Polymers 0.000 title claims description 76
- 239000002105 nanoparticle Substances 0.000 title claims description 71
- 238000000034 method Methods 0.000 title claims description 24
- 238000003018 immunoassay Methods 0.000 title claims description 23
- 102000004169 proteins and genes Human genes 0.000 claims description 74
- 108090000623 proteins and genes Proteins 0.000 claims description 74
- 238000003556 assay Methods 0.000 claims description 42
- 239000002245 particle Substances 0.000 claims description 35
- 238000003317 immunochromatography Methods 0.000 claims description 19
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 230000000295 complement effect Effects 0.000 claims description 12
- 239000000696 magnetic material Substances 0.000 claims description 12
- 239000012491 analyte Substances 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- -1 antibody Substances 0.000 claims description 8
- 229960002685 biotin Drugs 0.000 claims description 8
- 235000020958 biotin Nutrition 0.000 claims description 8
- 239000011616 biotin Substances 0.000 claims description 8
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 8
- 239000003446 ligand Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000008346 aqueous phase Substances 0.000 claims description 2
- 239000012466 permeate Substances 0.000 claims description 2
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/545—Synthetic resin
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Nanotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
Description
Method and Imunoassay Employing Polystyrene Nano-Particles1. A method for immunoassay, which employs nano-meter sized polystyrene (polystyrene nano-particle), wherein said polystyrene nano-particles are coated with proteins.
2. The method of claim 1, wherein said polystyrene nano-particles are colored.
3. The method of claim 1, wherein said polystyrene nana-particles are divided into at least one particle group, particles in different groups being coated with different proteins, for detecting at least one analyte.
4. The method of claim 1, wherein said polystyrene nano-particles have at least one size, particles of different sizes being coated with different proteins, for detecting at least one analyte.
5. The method of combination of claim ~ and 4.
6. The method of claim 3, 4 and 5, wherein said polystyrene nano-particles are colored with at least one color.
7. The method of claim 1,2,3,4,5, and b, wherein said polystyrene nano-particles are in size range of 3nm to 200nm.
8. The method of claim 1,2,3,4,5, and 6, wherein said coated proteins are antigen, antibody, acceptor, or ligand.
9. An immunoassay, which employs polystyrene nano-paxticle, wherein said polystyrene nano-particles are coated with proteins.
10. The immunoassay of claim 9, wherein said polystyrene nano-particles are colored.
11. The immunoassay of claim 9, wherein said polystyrene nano-particles are divided into at least one particle group, particles in different groups being coated with different proteins, for detecting at least one analyte.
12. The immunoassay of claim 9, wherein said polystyrene nano-particles have at least one size, particles of different sizes being coated with different proteins, for detecting at least one analyte.
13. The immunoassay of combination of claim 11 and 12.
14. The immunoassay of claim 1 l, 12 and 13, wherein said polystyrene nano-particles are colored with at least one color.
15. The immunoassay of claim 9, 10, 11, 12, 13, and 14, wherein said polystyrene nano-particles are in size range of 3nm to 200nm.
16. The immunoassay of claim 9, 10, 11, 12, 13, and 14, wherein said coated proteins are antigen, antibody, acceptor, or ligand.
17. An immunochromatography assay, which employs polystyrene nano-particle, wherein said polystyrene nano-particles are coated with proteins.
18. The immunochromatography assay of claim 17, wherein said polystyrene nano-particles have at least one size, being divided into at least one particle group, and being colored with at least one color, being in size range of 3nrn to 200nm;
said coated proteins are antigen, antibody, acceptor, or ligand.
said coated proteins are antigen, antibody, acceptor, or ligand.
19. The immunochromatography assay of claim 18, wherein said assay includes three areas in sequence:
a) a sample receiving area, for receiving a liquid sample to be tested;
b) a conjugate area having therein or thereon said polystyrene nano-particles in dry state;
c) a read-out area having at least one defined zone, wherein on each said defined zone a complementary binding partner protein to a protein on said particle is immobilized.
the immunochromatography assay works by adding the liquid sample to said sample receiving area ,when said sample passing said conjugate area polystyrene nano-particles of one or more sizes being released and moving forward together with said sample, said sample carrying said released polystyrene nano-particles is then passing said read-out area, said released polystyrene nano-particles are thus detected when said sample passes said defined zones) in said read-out area, and the analyte in the sample are therefore detected qualitatively and/or quantitatively.
a) a sample receiving area, for receiving a liquid sample to be tested;
b) a conjugate area having therein or thereon said polystyrene nano-particles in dry state;
c) a read-out area having at least one defined zone, wherein on each said defined zone a complementary binding partner protein to a protein on said particle is immobilized.
the immunochromatography assay works by adding the liquid sample to said sample receiving area ,when said sample passing said conjugate area polystyrene nano-particles of one or more sizes being released and moving forward together with said sample, said sample carrying said released polystyrene nano-particles is then passing said read-out area, said released polystyrene nano-particles are thus detected when said sample passes said defined zones) in said read-out area, and the analyte in the sample are therefore detected qualitatively and/or quantitatively.
20. The immunochromatography assay of claim 19, wherein said defined zones) at said read-out area have line shape.
21. The imrnunochromatography assay of claim 20, wherein said lines) are arranged in the following order:
the complementary binding partner proteins) immobilized to said lines) closer to said conjugate area correspond to said proteins) coated on larger size particles and the closer said line to said conjugate area the larger said corresponding particle size; on the contrary, the complementary binding partner proteins) immobilized to said lines) farther to said conjugate area corresponds to said proteins) coated on smaller size particles and the farther said line to said conjugate area the smaller said corresponding particle size o 22. The immunochromatography assay of claim 19, wherein said defined zones) at said read-out area have spot shape.
the complementary binding partner proteins) immobilized to said lines) closer to said conjugate area correspond to said proteins) coated on larger size particles and the closer said line to said conjugate area the larger said corresponding particle size; on the contrary, the complementary binding partner proteins) immobilized to said lines) farther to said conjugate area corresponds to said proteins) coated on smaller size particles and the farther said line to said conjugate area the smaller said corresponding particle size o 22. The immunochromatography assay of claim 19, wherein said defined zones) at said read-out area have spot shape.
23. The immunochromatography assay of claim 19, wherein said defined zones at said read-out area have spot shapes, forming a spot matrix.
24. The immunochromatography assay of claim 22 and 23, wherein said spots) are arranged in the following order:
the complementary binding partner proteins) immobilized to said spots) closer to said conjugate area correspond to said proteins) coated on larger size particles and the closer said spot to said conjugate area the larger said corresponding particle size; on the contrary, the complementary binding partner proteins) immobilized to said spots) farther to said conjugate area corresponds to the proteins) coated on smaller size particles and the farther said spot to said conjugate area the smaller said corresponding particle size.
the complementary binding partner proteins) immobilized to said spots) closer to said conjugate area correspond to said proteins) coated on larger size particles and the closer said spot to said conjugate area the larger said corresponding particle size; on the contrary, the complementary binding partner proteins) immobilized to said spots) farther to said conjugate area corresponds to the proteins) coated on smaller size particles and the farther said spot to said conjugate area the smaller said corresponding particle size.
25. An immunofiltration assay, which employs polystyrene nano-particles, wherein said polystyrene nano-particles are coated with proteins.
26. The immunofiltration assay of claim 25, wherein said polystyrene nano-particles have at least ane size, being divided into at least one particle group, and being colored with at least one color, being in size range of 3nm to 200nm; said coated proteins are antigen, antibody, acceptor, or ligand.
27 . The immunofiltration assay of claim 26, wherein said polystyrene nano-particles are in aqueous phase, and wherein said assay includes a filter, on which there is at least one defined zone on that a complementary binding partner protein to a protein on said polystyrene nano-particles is immobilized.
the immunofiltration assay works by adding the liquid sample to said filter and said sample permeates said filter, said aqueous polystyrene nano-particles coated with proteins are then added to said filter, said polystyrene nano-particles are thus detected in the defined zone(s), and the analyze in said sample are therefore detected qualitatively and/or quantitatively.
the immunofiltration assay works by adding the liquid sample to said filter and said sample permeates said filter, said aqueous polystyrene nano-particles coated with proteins are then added to said filter, said polystyrene nano-particles are thus detected in the defined zone(s), and the analyze in said sample are therefore detected qualitatively and/or quantitatively.
28. The immunofiltration assay of claim 27, wherein said defined zones) have line shape.
29. The immunofiltration assay of claim 27, wherein said defined zones) have spot shape.
30. The immunofiltration assay of claim 27, wherein said defined zones have spot shapes, forming a spot matrix.
31. The method of claims1,2,3,4,5,6,7,and 8, wherein said protein coated to said polystyrene nano-particle is labeled with enzyme, fluorescein, biotin, isotope, magnetic material, and/or luminescent material.
32. The assay of claims9,10,11,12,13,14,15 and 16, wherein said protein coated to said polystyrene nano-particle is labeled with enzyme, fluorescein, biotin, isotope, magnetic material, and/or luminescent material.
33. The immunochromatography assay of claims17,18,19~,20, 21, 22, 23 and 24, wherein said protein coated to said polystyrene nano-particles is labeled with enzyme, fluorescein, biotin, isotope, magnetic material, and/or luminescent material.
34. The immunofiltration assay of claims 25,26,27,28,29 and 30, wherein said protein coated to said polystyrene nano-particles is labeled with enzyme, fluorescein, biotin, isotope, magnetic material, andlor luminescent material.
35. A method for immunoassay, which employs polystyrene nano-particles in the size of 3nm to 200nm, coated with protein such as antigen or antibody, wherein said protein is immobilized to a solid support.
36. An immunoassay, which employs polystyrene nano-particles in the size of 3nm to 200nm, coated with protein such as antigen or antibody, wherein said protein is immobilized to a solid support.
37. A method for imrnuno-separation, which employs polystyrene nano-particles in the size of 3nm to 200nm, coated with proteins such as antigen or antibody, wherein said protein is labeled by magnetic material.
38. An apparatus for immuno-separation, which employs polystyrene nano-particles in the size of 3nm to 200nm, coated with proteins such as antigen or antibody, wherein said protein is labeled by magnetic material.
Claims (38)
1. A method for immunoassay, which employs nano-meter sized polystyrene (polystyrene nano-particle), wherein said polystyrene nano-particles are coated with proteins.
2. The method of claim 1, wherein said polystyrene nano-particles are colored.
3. The method of claim 1, wherein said polystyrene nano-particles are divided into at least one particle group, particles in different groups being coated with different proteins, for detecting at least one analyte.
4. The method of claim 1, wherein said polystyrene nano-particles have at least one size, particles of different sizes being coated with different proteins, for detecting at least one analyte.
5. The method of combination of claim 3 and 4.
6. The method of claim 3, 4 and 5, wherein said polystyrene nano-particles are colored with at least one color.
7. The method of claim 1,2,3,4,5, and 6, wherein said polystyrene nano-particles are in size range of 3nm to 200nm.
8. The method of claim 1,2,3,4,5, and 6, wherein said coated proteins are antigen, antibody, acceptor, or ligand.
9. An immunoassay, which employs polystyrene nano-particle, wherein said polystyrene nano-particles are coated with proteins.
10. The immunoassay of claim 9, wherein said polystyrene nano-particles are colored.
11. The immunoassay of claim 9, wherein said polystyrene nano-particles are divided into at least one particle group, particles in different groups being coated with different proteins, for detecting at least one analyte.
12. The immunoassay of claim 9, wherein said polystyrene nano-particles have at least one size, particles of different sizes being coated with different proteins, for detecting at least one analyte.
13. The immunoassay of combination of claim 11 and 12.
14. The immunoassay of claim 11, 12 and 13, wherein said polystyrene nano-particles are colored with at least one color.
15. The immunoassay of claim 9, 10, 11, 12, 13, and 14, wherein said polystyrene nano-particles are in size range of 3nm to 200nm.
16. The immunoassay of claim 9, 10, 11, 12, 13, and 14, wherein said coated proteins are antigen, antibody, acceptor, or ligand.
17. An immunochromatography assay, which employs polystyrene nano-particle, wherein said polystyrene nano-particles are coated with proteins.
18. The immunochromatography assay of claim 17, wherein said polystyrene nano-particles have at least one size, being divided into at least one particle group, and being colored with at least one color, being in size range of 3nrn to 200nm;
said coated proteins are antigen, antibody, acceptor, or ligand.
said coated proteins are antigen, antibody, acceptor, or ligand.
19. The immunochromatography assay of claim 18, wherein said assay includes three areas in sequence:
a) a sample receiving area, for receiving a liquid sample to be tested;
b) a conjugate area having therein or thereon said polystyrene nano-particles in dry state;
c) a read-out area having at least one defined zone, wherein on each said defined zone a complementary binding partner protein to a protein on said particle is immobilized.
the immunochromatography assay works by adding the liquid sample to said sample receiving area ,when said sample passing said conjugate area polystyrene nano-particles of one or more sizes being released and moving forward together with said sample, said sample carrying said released polystyrene nano-particles is then passing said read-out area, said released polystyrene nano-particles are thus detected when said sample passes said defined zones) in said read-out area, and the analyte in the sample are therefore detected qualitatively and/or quantitatively.
a) a sample receiving area, for receiving a liquid sample to be tested;
b) a conjugate area having therein or thereon said polystyrene nano-particles in dry state;
c) a read-out area having at least one defined zone, wherein on each said defined zone a complementary binding partner protein to a protein on said particle is immobilized.
the immunochromatography assay works by adding the liquid sample to said sample receiving area ,when said sample passing said conjugate area polystyrene nano-particles of one or more sizes being released and moving forward together with said sample, said sample carrying said released polystyrene nano-particles is then passing said read-out area, said released polystyrene nano-particles are thus detected when said sample passes said defined zones) in said read-out area, and the analyte in the sample are therefore detected qualitatively and/or quantitatively.
20. The immunochromatography assay of claim 19, wherein said defined zone(s) at said read-out area have line shape.
21. The immunochromatography assay of claim 20, wherein said line(s) are arranged in the following order:
the complementary binding partner protein(s) immobilized to said line(s) closer to said conjugate area correspond to said protein(s) coated on larger size particles and the closer said line to said conjugate area the larger said corresponding particle size; on the contrary, the complementary binding partner protein(s) immobilized to said line(s) farther to said conjugate area corresponds to said protein(s) coated on smaller size particles and the farther said line to said conjugate area the smaller said corresponding particle size.
the complementary binding partner protein(s) immobilized to said line(s) closer to said conjugate area correspond to said protein(s) coated on larger size particles and the closer said line to said conjugate area the larger said corresponding particle size; on the contrary, the complementary binding partner protein(s) immobilized to said line(s) farther to said conjugate area corresponds to said protein(s) coated on smaller size particles and the farther said line to said conjugate area the smaller said corresponding particle size.
22. The immunochromatography assay of claim 19, wherein said defined zone(s) at said read-out area have spot shape.
23. The immunochromatography assay of claim 19, wherein said defined zones at said read-out area have spot shapes, forming a spot matrix.
24. The immunochromatography assay of claim 22 and 23, wherein said spots) are arranged in the following order:
the complementary binding partner protein(s) immobilized to said spot(s) closer to said conjugate area correspond to said protein(s) coated on larger size particles and the closer said spot to said conjugate area the larger said corresponding particle size; on the contrary, the complementary binding partner protein(s) immobilized to said spot(s) farther to said conjugate area corresponds to the protein(s) coated on smaller size particles and the farther said spot to said conjugate area the smaller said corresponding particle size.
the complementary binding partner protein(s) immobilized to said spot(s) closer to said conjugate area correspond to said protein(s) coated on larger size particles and the closer said spot to said conjugate area the larger said corresponding particle size; on the contrary, the complementary binding partner protein(s) immobilized to said spot(s) farther to said conjugate area corresponds to the protein(s) coated on smaller size particles and the farther said spot to said conjugate area the smaller said corresponding particle size.
25. An immunofiltration assay, which employs polystyrene nano-particles, wherein said polystyrene nano-particles are coated with proteins.
26. The immunofiltration assay of claim 25, wherein said polystyrene nano-particles have at least one size, being divided into at least one particle group, and being colored with at least one color, being in size range of 3nm to 200nm; said coated proteins are antigen, antibody, acceptor, or ligand.
27 . The immunofiltration assay of claim 26, wherein said polystyrene nano-particles are in aqueous phase, and wherein said assay includes a filter, on which there is at least one defined zone on that a complementary binding partner protein to a protein on said polystyrene nano-particles is immobilized.
the immunofiltration assay works by adding the liquid sample to said filter and said sample permeates said filter, said aqueous polystyrene nano-particles coated with proteins are then added to said filter, said polystyrene nano-particles are thus detected in the defined zone(s), and the analyze in said sample are therefore detected qualitatively and/or quantitatively.
the immunofiltration assay works by adding the liquid sample to said filter and said sample permeates said filter, said aqueous polystyrene nano-particles coated with proteins are then added to said filter, said polystyrene nano-particles are thus detected in the defined zone(s), and the analyze in said sample are therefore detected qualitatively and/or quantitatively.
28. The immunofiltration assay of claim 27, wherein said defined zone(s) have line shape.
29. The immunofiltration assay of claim 27, wherein said defined zone(s) have spot shape.
30. The immunofiltration assay of claim 27, wherein said defined zones have spot shapes, forming a spot matrix.
31. The method of claims 1,2,3,4,5,6,7,and 8, wherein said protein coated to said polystyrene nano-particle is labeled with enzyme, fluorescein, biotin, isotope, magnetic material, and/or luminescent material.
32. The assay of claims 9,10,11,12,13,14,15 and 16, wherein said protein coated to said polystyrene nano-particle is labeled with enzyme, fluorescein, biotin, isotope, magnetic material, and/or luminescent material.
33. The immunochromatography assay of claims 17,18,19,20, 21, 22, 23 and 24, wherein said protein coated to said polystyrene nano-particles is labeled with enzyme, fluorescein, biotin, isotope, magnetic material, and/or luminescent material.
34. The immunofiltration assay of claims 25,26,27,28,29 and 30, wherein said protein coated to said polystyrene nano-particles is labeled with enzyme, fluorescein, biotin, isotope, magnetic material, and/or luminescent material.
35. A method for immunoassay, which employs polystyrene nano-particles in the size of 3nm to 200nm, coated with protein such as antigen or antibody, wherein said protein is immobilized to a solid support.
36. An immunoassay, which employs polystyrene nano-particles in the size of 3nm to 200nm, coated with protein such as antigen or antibody, wherein said protein is immobilized to a solid support.
37. A method for immuno-separation, which employs polystyrene nano-particles in the size of 3nm to 200nm, coated with proteins such as antigen or antibody, wherein said protein is labeled by magnetic material.
38. An apparatus for immuno-separation, which employs polystyrene nano-particles in the size of 3nm to 200nm, coated with proteins such as antigen or antibody, wherein said protein is labeled by magnetic material.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002431113A CA2431113A1 (en) | 2003-06-10 | 2003-06-10 | Method and immunoassay employing polystyrene nano-particles |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002431113A CA2431113A1 (en) | 2003-06-10 | 2003-06-10 | Method and immunoassay employing polystyrene nano-particles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2431113A1 true CA2431113A1 (en) | 2004-12-10 |
Family
ID=33557558
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002431113A Abandoned CA2431113A1 (en) | 2003-06-10 | 2003-06-10 | Method and immunoassay employing polystyrene nano-particles |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2431113A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2331681A1 (en) * | 2008-06-26 | 2010-01-12 | Universidad De Zaragoza | IMMUNOCROMATOGRAPHIC METHOD TO DETECT THE PRESENCE OF ALLERGENS IN PROCESSED FOODS. |
| WO2021109059A1 (en) * | 2019-12-05 | 2021-06-10 | 复旦大学 | Long-afterglow luminescent styrene polymer microsphere, preparation method therefor and application thereof |
-
2003
- 2003-06-10 CA CA002431113A patent/CA2431113A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2331681A1 (en) * | 2008-06-26 | 2010-01-12 | Universidad De Zaragoza | IMMUNOCROMATOGRAPHIC METHOD TO DETECT THE PRESENCE OF ALLERGENS IN PROCESSED FOODS. |
| WO2021109059A1 (en) * | 2019-12-05 | 2021-06-10 | 复旦大学 | Long-afterglow luminescent styrene polymer microsphere, preparation method therefor and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7858396B2 (en) | Lateral flow assay device with multiple equidistant capture zones | |
| CA2469935C (en) | Diagnostic testing process | |
| US7033747B2 (en) | Multi-parameter assays including analysis discs and methods relating thereto | |
| KR101072756B1 (en) | - Reduction of the Hook Effect in Membrane-Based Assay Devices | |
| KR101266244B1 (en) | Multi-functional and configurable assays | |
| KR20070040375A (en) | Lateral flow device for detection of large pathogens | |
| JP2008538609A (en) | Multiplex microparticle system | |
| JP2007502998A (en) | Apparatus for analyzing or separating nanometer structures, and its fabrication method and application | |
| JP2007502998A5 (en) | ||
| EP2856162B1 (en) | Microplates with enhanced immobilisation capabilities controlled by magnetic field | |
| WO2015135840A1 (en) | Method and device for determining biological analytes | |
| KR101057918B1 (en) | Reduction of hook effects in the analysis device | |
| US6887377B2 (en) | Affinity matrices with enhanced visibility for molecular pull-down and immunoprecipitation applications | |
| US8029985B2 (en) | Amplified bioassay | |
| US20130122517A1 (en) | Method of performing an assay | |
| JP2006505766A (en) | Multi-parameter tests including analytical discs and related methods | |
| US6399299B1 (en) | Amplified array analysis system | |
| US6267969B1 (en) | Unit-of-use reagent composition for specific binding assays | |
| JP2000097944A (en) | Kits for immunochromatography | |
| CA2431113A1 (en) | Method and immunoassay employing polystyrene nano-particles | |
| US20120225422A1 (en) | Method and device employing a non-receptor ligand interaction with nanoparticles or other solid phase followed by specific detection | |
| JP7369017B2 (en) | Analyte detection sensitization method using colloidal particles | |
| EP0607209B1 (en) | Unit-of-use reagent compositions for specific binding assays | |
| EP0973034A1 (en) | Immunoassays and devices therefor | |
| Sharma et al. | Identification of analyte of interest through lateral flow assay |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |